• Sun. Nov 27th, 2022

Marinus to sell rare-disease voucher to Novo Nordisk for $110 million


Jul 15, 2022 , , ,
Boeing stock jumps nearly 8% after maker's commercial-jet deliveries rise more than 50% in Q2

Shares of Marinus Pharmaceuticals Inc.

gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to Novo Nordisk
Marinus CFO Steven Pfanstiel told investors in a news release that the sale “extends our cash runway into the fourth quarter of 2023.” Marinus received the voucher in March after it received approval from the Food and Drug Administration for Ztalmy, its treatment for seizures associated with a rare form of epilepsy. The company’s stock has tumbled 53.3% this year, while the S&P 500

is down 20.3%.

Image and article originally from www.marketwatch.com. Read the original article here.